USP Drug Supply Map Reviews Global API Manufacturing
A new report released by USP offers insight into API supply chain vulnerabilities.
US Pharmacopeia (USP), an independent scientific organization, announced on March 16, 2022 that its USP Medicine Supply Vulnerability Insights series reveals vulnerabilities in global API supply.
The first published finding in the series discusses the importance of large Indian facilities in manufacturing APIs. There are currently 114 installations in India with over 30 active US-approved API products, which is significantly higher than any other region in the world.
The 40 external datasets and 250 million data points provided by the drug supply map provide a comprehensive view of the upstream pharmaceutical supply chain. This information can help guide regulatory actions to protect against overly concentrated sources of APIs and build supply resilience.
“The USP Drug Supply Map is an innovative early warning system to help identify ingredients and finished products at risk of shortages so suppliers, manufacturers and governments can take action to help prevent the shortage,” commented Ronald T. Piervincenzi, CEO of USP. “Without visibility into the drug supply chain, preparing for the next crisis is not possible.”
“The USP Drug Supply Map helps us identify vulnerabilities upstream in the supply chain for various essential drugs and determine where Phlow’s advanced manufacturing capabilities may have the greatest impact,” added Dave Levin, MD, Chief Medical Officer and Chief Information Officer of Phlow Corp. ., a pharmaceutical company based in the United States.